Smith & Nephew Snats (SNN) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Smith & Nephew reported a 4% revenue growth in Q3 2024, reaching $1,412 million, despite facing challenges in China. The company’s Advanced Wound Management segment showed significant acceleration, while Sports Medicine and Orthopaedics also contributed to the positive performance, driven by the 12-Point Plan improvements. Looking ahead, the company anticipates revenue growth to continue, albeit with caution due to ongoing headwinds in China.
For further insights into SNN stock, check out TipRanks’ Stock Analysis page.
